PR88781

WETTEREN, Belgium, March 31, 2021 /PRNewswire=KYODO JBN/ --

Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of

biopharmaceutical contract development and manufacturing services, is pleased

to announce a manufacturing agreement expansion with AstraZeneca to include

drug product manufacturing.

Logo - https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg  

This agreement expands the scope of Aji Bio-Pharma's service offerings to

AstraZeneca to include aseptic fill finish services at its San Diego,

California facility, in addition to small molecule manufacturing services

proceeding in Belgium.

"We are excited to expand our manufacturing agreement with AstraZeneca and to

support them with additional service offerings," said Magnus Busch, Global

Account Manager, Ajinomoto Bio-Pharma Services. "Our San Diego team is proud to

join our Belgium colleagues in support of AstraZeneca. This expanded agreement

builds on our commitment to be a leading, trusted, innovative partner to our

clients."

About Ajinomoto Bio-Pharma Services

Ajinomoto Bio-Pharma Services is a fully integrated contract development and

manufacturing organization with sites in Belgium, United States, Japan, and

India, providing comprehensive development, cGMP manufacturing, and aseptic

fill finish services for small and large molecule APIs and intermediates.

Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and

capabilities for pre-clinical and pilot programs to commercial quantities,

including Corynex(R) protein expression technology, oligonucleotide synthesis,

antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis,

continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is

dedicated to providing a high level of quality and service to meet our client's

needs. Learn more: www.AjiBio-Pharma.com

SOURCE  Ajinomoto Bio-Pharma Services

CONTACT: Ajinomoto Contact: info@us.ajibio-pharma.com